• Skip to Content

.

 Indiana University Indiana University IU

Search

IU Simon Comprehensive Cancer Center Indiana University Melvin and Bren Simon Comprehensive Cancer CenterA National Cancer Institute Comprehensive Cancer Center

  • About Us
    • Our Mission & Goals
    • Our Leadership
    • Our Members (Scientists, Physician-scientists)
    • Our Partners
    • Travel
  • Research & Clinical Trials
    • Clinical Trials
    • Research Programs
    • DHART SPORE
    • Member Directory
    • Become a Member
    • Shared Facilities
    • Research Resources
    • Funding Opportunities
    • Refer a Patient
  • Career Enhancement & Related Activities
    • Aims
    • Training Programs
    • Trainee Membership
    • Fellowships
    • Presentations
    • Cancer Research Day
    • Amelia Project
    • Andrea Gianaris Pancreatic Cancer Symposium
    • William J. Wright Scholarship Fund
  • News & Publications
    • News
    • News Archives
    • Publications
  • Office of Community Outreach & Engagement
  • Giving
Staff Login
  • Patient Care at IU Health
  • IU School of Medicine
  • Research & Clinical Trials
  • Clinical Trials
  • Find a Trial
  • Trial Results

Research & Clinical Trials

Find a Trial

Trial Results


3 protocol(s) meet the specified criteria
PHO-COG-ANBL1531OPEN TO ACCRUAL
A Phase 3 Study of 131-I-Metaiodobenzylguanidine (131-I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
PHO-COG-ARST2031OPEN TO ACCRUAL
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
PHO-FALLON-COG-ARST1431OPEN TO ACCRUAL
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Clinical Trials
    • About Clinical Trials
    • Should I Participate?
    • Find a Trial
      • by Cancer Type
      • by Doctor
      • by Institution
    • Biobanking: Donating a Part of You to Help Find a Cure.
    • Scientific Review Committee Resources
  • Research Programs
  • DHART SPORE
  • Member Directory
  • Become a Member
  • Shared Facilities
  • Research Resources
  • Funding Opportunities
  • Refer a Patient
NCI-CC A Cancer Center Designated by the National Cancer Institute Big 10 Cancer Research Consortium
Give Now
Fundraising Disclosures: http://go.iu.edu/89n

Block IU Copyright ©  The Trustees of Indiana University, Copyright Complaints, Privacy Notice

Indiana University Melvin and Bren Simon Comprehensive Cancer Center | 535 Barnhill Drive | Indianapolis, IN 46202
Patient Care: (888) 600-4822 | Administrative Office: (317) 278-0070

For accessibility or website issues, contact the webmaster.